Pricing
  1. US-listed companies
  2. Emergent BioSolutions Inc.
  3. Financials
  4. Cash from investing

Emergent BioSolutions Inc. (EBS)

Market cap
$446.71M
P/E ratio
SummaryFinancials
Period EndCash from investing (Million USD)YoY (%)
Dec 31, 2024125-41.03%
Dec 31, 2023212-155.68%
Dec 31, 2022-381+69.47%
Dec 31, 2021-225+49.01%
Dec 31, 2020-151+55.83%
Dec 31, 2019-97-89.20%
Dec 31, 2018-897+258.98%
Dec 31, 2017-250+227.75%
Dec 31, 2016-76+67.74%
Dec 31, 2015-45-33.04%
Dec 31, 2013-68+69.25%
Dec 31, 2012-40-25.66%
Dec 31, 2011-54

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat